|
Ronald W. Mink, Ph.D. was promoted to the position of Chief Science Officer (CSO) in July 2005. Prior to being appointed as Chief Scientific Officer, Dr. Mink had served as Director of R&D at Calypte since joining the Company in February 2001. Prior to joining Calypte, he was the Director of Research and Development at OraSure Technologies, Inc. (NASDAQ: OSUR). At OraSure, Dr. Mink was the inventor of the first OraQuick HIV-1 rapid prototypes (U.S. Patent 6,303,081), supervised the OraQuick research and development effort and oversaw product transfer to production. Prior experience in the rapid develop arena includes such companies as Eli Lilly and Co. in their diagnostic group and Carter Wallace. | 